Pheochromocytomas and paragangliomas in patients with congenital heart defects
- 1 February 2026
- journal article
- Published by Endocrinology Research Centre in Endocrine Surgery
- Vol. 19 (3) , 54-62
Abstract
The correlation between pheochromocytoma/paraganglioma (PHEO/PGL) and cyanotic congenital heart defects is rare but not coincidental. Research suggests that the development of PHEO/PGL in these patients maybe explained by chronic hypoxia, disruptions in the sympathetic nervous system, and potential genetic predisposition. These factors may provoke the tumor transformation of chromaffin cells. Additionally, diagnosing PHEO/PGL in patients with heart defects is complicated by hemodynamic disturbances that mask the characteristic sympathoadrenal crises of PHEO/PGL. The occurrence of these neoplasms can exacerbate the clinical course of congenital defects due to increased catecholamine secretion, leading to vasoconstriction and worsening hypoxia. We present two clinical cases of PHEO/PGL in the context of congenital heart defects, with patients observed and treated at the N.N. Blokhin National Medical Research Center of Oncology and the A.N. Bakoulev National Medical Research Center of Cardiovascular Surgery. These observations emphasize the importance of vigilance for symptoms of tachycardia and uncontrolled hypertension in such patients. Despite their rarity, the relationship between these pathologies must be considered for accurate diagnosis and optimal treatment selection.Keywords
This publication has 22 references indexed in Scilit:
- Comparison of plasma metanephrines in patients with cyanotic and acyanotic congenital heart diseaseEndocrine, 2022
- Emerging Treatments for Advanced/Metastatic Pheochromocytoma and ParagangliomaCurrent Treatment Options in Oncology, 2020
- Asymptomatic phaeochromocytoma in a patient with Holt-Oram syndrome: a case reportEuropean Heart Journal - Case Reports, 2019
- Comprehensive Molecular Characterization of Pheochromocytoma and ParagangliomaCancer Cell, 2017
- Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancerPharmacology & Therapeutics, 2016
- The Protean Manifestations of PheochromocytomaHormone and Metabolic Research, 2009
- Cardiac malformations, adrenal agenesis, neural crest defects and exencephaly in mice lacking Cited2, a new Tfap2 co-activatorNature Genetics, 2001
- Congenital Heart Disease in AdultsNew England Journal of Medicine, 2000
- Cyanotic congenital heart disease with malignant paragangliomaCancer, 1982
- High altitude hypoxia and chemodectomasHuman Pathology, 1973